Patients as Partners in Lymphatic Medicine | Dr. Rafid Fadul, ARPA-H | LE&RN Advocacy Day 2026
Description: In the 1980s, a mother named Sue Byrnes was told her daughter's rare lung disease, LAM, was more or less a death sentence. She refused to accept that. She started a foundation, funded the research and pushed it forward, and in 2015 the FDA approved a treatment. Dr. Rafid Fadul, Deputy Director and Chief Medical Officer of ARPA-H, opens with that story, then explains why patients and caregivers belong at the center of health innovation, why ARPA-H's lymphatic programs LIGHT and GLIDE require every research team to embed a patient or caregiver in the science, and what the next ten years could mean for a new field of lymphatic medicine. LE&RN Advocacy Day 2026 was made possible by the generous support of our Premier Sponsors: Celltaxis, Diagnostic Green, Juzo, Lympha Press and Tactile Medical.
